Merck & Co Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.4%projected annual EPS growth
Analyst Coverage
26analysts covering
FY Revenue (est.)
$67.1Bnext fiscal year
FY EPS (est.)
$2.75next fiscal year
Monitoring Framework
Key Performance Indicators
Keytruda (pembrolizumab) and Keytruda SC (subcutaneous) Combined Global Sales Quarterly8BTarget: Peak sales of $33B to $34B by 2028
Winrevair (sotatercept) Global Sales Quarterly5.3BTarget: Continued rapid expansion to offset Keytruda LOE
Watch Items
- Keytruda (pembrolizumab) Loss of Exclusivity (LOE) and Biosimilar EntryTrigger: Primary U.S. patent expiration in late 2028 / secondary patents extending to November 2029Action: Monitor market share retention (MSR) and time-to-erosion (TTE) metrics; track conversion rates to subcutaneous Keytruda Qlex formulation.
- Pipeline Diversification and M&A IntegrationTrigger: Closing of major acquisitions (e.g., Terns Pharmaceuticals for $6.7B, Cidara Therapeutics)Action: Track clinical trial milestones for acquired assets and manage one-time R&D charges impacting GAAP EPS.
Research as of 2 Sep 2026